Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCART123 in newly diagnosed adverse genetic risk AML
NCT04106076Phase 1Withdrawn
- Sponsor
- Cellectis
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of UCART123 in acute myeloid leukemia (AML), sponsored by Cellectis. Primary endpoint: Incidence of AE/SAE/DLT at 24 months. Planned start Jul 2019; status: withdrawn.
02
Drugs
UCART123
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04106076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04106076.